Advertisement
Screener

EXAGEN INC. (XGN) Selling, General and Administrative Expense

2.8 / 5 stars · 68/120 Roast Me

EXAGEN INC. Selling, General and Administrative Expense

EXAGEN INC. (XGN) reported Selling, General and Administrative Expense of $12.51 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.

Financial Statements › Expense Statement › Operating Expenses

us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-08-04

  • EXAGEN INC. selling, general and administrative expense for the quarter ending 2026-06-30 was $12.51M, a 8.41% increase year-over-year.
  • EXAGEN INC. selling, general and administrative expense for the quarter ending 2026-03-31 was $12.07M, a 7.69% increase year-over-year.
  • EXAGEN INC. selling, general and administrative expense for the quarter ending 2025-12-31 was $12.42M, a 21.76% increase year-over-year.
  • EXAGEN INC. selling, general and administrative expense for the quarter ending 2025-09-30 was $11.45M, a 12.61% increase year-over-year.
  • EXAGEN INC. selling, general and administrative expense for fiscal 2025 was $46.62M, a 12.67% increase from fiscal 2024.
  • EXAGEN INC. selling, general and administrative expense for fiscal 2024 was $41.37M, a 12.77% decline from fiscal 2023.
  • EXAGEN INC. selling, general and administrative expense for fiscal 2023 was $47.43M, a 8.82% decline from fiscal 2022.
  • EXAGEN INC. selling, general and administrative expense for fiscal 2022 was $52.02M, a 16.79% increase from fiscal 2021.
Period endSelling, General and Administrative Expense 3 monthSelling, General and Administrative Expense 6 monthSelling, General and Administrative Expense 9 monthSelling, General and Administrative Expense 12 month
2026-06-30$12.51M
10-Q · filed 2026-08-04
$24.58M
10-Q · filed 2026-08-04
$37.00M
derived: sum of 3 quarters · filed 2026-08-04
$48.45M
derived: sum of 4 quarters · filed 2026-08-04
2026-03-31$12.07M
10-Q · filed 2026-05-11
$24.49M
derived: sum of 2 quarters · filed 2026-05-11
$35.94M
derived: sum of 3 quarters · filed 2026-05-11
$47.48M
derived: sum of 4 quarters · filed 2026-08-04
2025-12-31$12.42M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10
$23.87M
derived: sum of 2 quarters · filed 2026-03-10
$35.41M
derived: sum of 3 quarters · filed 2026-08-04
$46.62M
10-K · filed 2026-03-10
2025-09-30$11.45M
10-Q · filed 2025-11-04
$22.99M
derived: sum of 2 quarters · filed 2026-08-04
$34.19M
10-Q · filed 2025-11-04
$44.40M
derived: sum of 4 quarters · filed 2026-08-04
2025-06-30$11.54M
10-Q · filed 2026-08-04
$22.75M
10-Q · filed 2026-08-04
$32.95M
derived: sum of 3 quarters · filed 2026-08-04
$43.11M
derived: sum of 4 quarters · filed 2026-08-04
2025-03-31$11.20M
10-Q · filed 2026-05-11
$21.41M
derived: sum of 2 quarters · filed 2026-05-11
$31.57M
derived: sum of 3 quarters · filed 2026-05-11
$42.03M
derived: sum of 4 quarters · filed 2026-05-11
2024-12-31$10.20M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10
$20.37M
derived: sum of 2 quarters · filed 2026-03-10
$30.83M
derived: sum of 3 quarters · filed 2026-03-10
$41.37M
10-K · filed 2026-03-10
2024-09-30$10.16M
10-Q · filed 2025-11-04
$20.63M
derived: sum of 2 quarters · filed 2025-11-04
$31.17M
10-Q · filed 2025-11-04
$43.38M
derived: sum of 4 quarters · filed 2025-11-04
2024-06-30$10.46M
10-Q · filed 2025-07-29
$21.01M
10-Q · filed 2025-07-29
$33.22M
derived: sum of 3 quarters · filed 2025-07-29
$44.60M
derived: sum of 4 quarters · filed 2025-07-29
2024-03-31$10.54M
10-Q · filed 2025-05-05
$22.76M
derived: sum of 2 quarters · filed 2025-05-05
$34.13M
derived: sum of 3 quarters · filed 2025-05-05
$46.09M
derived: sum of 4 quarters · filed 2025-05-05
2023-12-31$12.22M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11
$23.59M
derived: sum of 2 quarters · filed 2025-03-11
$35.54M
derived: sum of 3 quarters · filed 2025-03-11
$47.43M
10-K · filed 2025-03-11
2023-09-30$11.38M
10-Q · filed 2024-11-12
$23.33M
derived: sum of 2 quarters · filed 2024-11-12
$35.21M
10-Q · filed 2024-11-12
$48.02M
derived: sum of 4 quarters · filed 2024-11-12
2023-06-30$11.95M
10-Q · filed 2024-08-05
$23.84M
10-Q · filed 2024-08-05
$36.65M
derived: sum of 3 quarters · filed 2024-08-05
$50.80M
derived: sum of 4 quarters · filed 2024-08-05
2023-03-31$11.88M
10-Q · filed 2024-05-13
$24.70M
derived: sum of 2 quarters · filed 2024-05-13
$38.85M
derived: sum of 3 quarters · filed 2024-05-13
$51.75M
derived: sum of 4 quarters · filed 2024-05-13
2022-12-31$12.81M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-18
$26.96M
derived: sum of 2 quarters · filed 2024-03-18
$39.87M
derived: sum of 3 quarters · filed 2024-03-18
$52.02M
10-K · filed 2024-03-18
2022-09-30$14.15M
10-Q · filed 2023-11-13
$27.05M
derived: sum of 2 quarters · filed 2023-11-13
$39.21M
10-Q · filed 2023-11-13
$51.01M
derived: sum of 4 quarters · filed 2023-11-13
2022-06-30$12.90M
10-Q · filed 2023-08-07
$25.05M
10-Q · filed 2023-08-07
$36.86M
derived: sum of 3 quarters · filed 2023-08-07
$48.38M
derived: sum of 4 quarters · filed 2023-08-07
2022-03-31$12.15M
10-Q · filed 2023-05-15
$23.95M
derived: sum of 2 quarters · filed 2023-05-15
$35.48M
derived: sum of 3 quarters · filed 2023-05-15
$46.65M
derived: sum of 4 quarters · filed 2023-05-15
2021-12-31$11.80M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-20
$23.33M
derived: sum of 2 quarters · filed 2023-03-20
$34.50M
derived: sum of 3 quarters · filed 2023-03-20
$44.54M
10-K · filed 2023-03-20
2021-09-30$11.53M
10-Q · filed 2022-11-21
$22.70M
derived: sum of 2 quarters · filed 2022-11-21
$32.74M
10-Q · filed 2022-11-21
$42.67M
derived: sum of 4 quarters · filed 2022-11-21
2021-06-30$11.17M
10-Q/A · filed 2022-11-21
$21.21M
10-Q/A · filed 2022-11-21
$31.14M
derived: sum of 3 quarters · filed 2022-11-21
$40.34M
derived: sum of 4 quarters · filed 2022-11-21
2021-03-31$10.04M
10-Q · filed 2022-05-11
$19.97M
derived: sum of 2 quarters · filed 2022-05-11
$29.17M
derived: sum of 3 quarters · filed 2022-05-11
$37.45M
derived: sum of 4 quarters · filed 2022-05-11
2020-12-31$9.93M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-22
$19.13M
derived: sum of 2 quarters · filed 2022-03-22
$27.41M
derived: sum of 3 quarters · filed 2022-03-22
$37.03M
10-K · filed 2022-03-22
2020-09-30$9.20M
10-Q · filed 2021-11-10
$17.48M
derived: sum of 2 quarters · filed 2021-11-10
$27.10M
10-Q · filed 2021-11-10
$35.02M
derived: sum of 4 quarters · filed 2021-11-10
2020-06-30$8.28M
10-Q · filed 2021-08-09
$17.90M
10-Q · filed 2021-08-09
$25.82M
derived: sum of 3 quarters · filed 2021-08-09
$33.12M
derived: sum of 4 quarters · filed 2021-08-09
2020-03-31$9.63M
10-Q · filed 2021-05-11
$17.54M
derived: sum of 2 quarters · filed 2021-05-11
$24.85M
derived: sum of 3 quarters · filed 2021-05-11
$32.15M
derived: sum of 4 quarters · filed 2021-05-11
2019-12-31$7.92M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16
$15.22M
derived: sum of 2 quarters · filed 2021-03-16
$22.52M
derived: sum of 3 quarters · filed 2021-03-16
$28.70M
10-K · filed 2021-03-16
2019-09-30$7.31M
10-Q · filed 2020-11-10
$14.61M
derived: sum of 2 quarters · filed 2020-11-10
$20.79M
10-Q · filed 2020-11-10
$26.04M
derived: sum of 4 quarters · filed 2020-11-10
2019-06-30$7.30M
10-Q · filed 2020-07-28
$13.48M
10-Q · filed 2020-07-28
$18.74M
derived: sum of 3 quarters · filed 2020-07-28
$23.67M
derived: sum of 4 quarters · filed 2020-07-28
2019-03-31$6.18M
10-Q · filed 2020-05-11
$11.44M
derived: sum of 2 quarters · filed 2020-05-11
$16.37M
derived: sum of 3 quarters · filed 2020-05-11
2018-12-31$5.26M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-25
$10.19M
derived: sum of 2 quarters · filed 2020-03-25
$19.68M
10-K · filed 2020-03-25
2018-09-30$4.93M
10-Q · filed 2019-11-12
$14.42M
10-Q · filed 2019-11-12

Similar stocks

Stock NameCountryMarket CapPE Ratio
Freenome, Inc. (FRNM)United States$0.143B
BIODESIX INC (BDSX)United States$0.312B
SERA PROGNOSTICS, INC. (SERA)United States$0.062B-5.75
AMERICAN SHARED HOSPITAL SERVICES (AMS)United States$0.010B-5.64
Advanced Biomed Inc. (ADVB)$0.009B
Aclarion, Inc. (ACON)United States$0.008B
BioNexus Gene Lab Corp (BGLC)$0.004B
Fulgent Genetics, Inc. (FLGT)United States$0.593B-6.70
Lumexa Imaging Holdings, Inc. (LMRI)United States$0.951B
CASTLE BIOSCIENCES INC (CSTL)United States$1.074B-37.45